RT GLP-3

Product Description

RT GLP-3 (LY3437943) represents the cutting-edge of multi-agonist peptide therapeutics, rationally designed as a triple agonist that simultaneously activates three distinct metabolic hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor (GCGR).

This triple agonism strategy builds upon the remarkable clinical success of dual GLP-1/GIP agonists like TR, which have shown unprecedented weight loss efficacy, by adding a third mechanism – glucagon receptor activation.

The pharmaceutical industry’s evolution in obesity therapeutics has progressed from single-target approaches (pure GLP-1 agonists like sm) to dual agonists (GLP-1/GIP like TR), and now to triple agonists like RT GLP-3 that attempt to orchestrate an even more comprehensive metabolic remodeling by simultaneously modulating multiple complementary pathways.

RT GLP-3 was specifically engineered with carefully optimized potencies at each of its three target receptors, balancing the appetite-suppressing and glucose-lowering effects of GLP-1 and GIP activation against the energy-expenditure-enhancing and fat-oxidizing effects of glucagon activation. This balancing act is critical because glucagon classically raises blood glucose (opposing insulin’s effects), but when combined with GLP-1 agonism, the glucose-raising effects are counteracted.

RT GLP-3 exerts its therapeutic effects through simultaneous and carefully balanced activation of three G-protein coupled receptors with distinct but complementary metabolic functions.

GLP-1 Receptor Activation

The GLP-1 receptor component provides effects that have become the cornerstone of modern obesity pharmacotherapy: activation of GLP-1 receptors in the hypothalamus and brainstem powerfully suppresses appetite and induces satiety through effects on proopiomelanocortin (POMC) neurons and other appetite-regulatory circuits, leading to substantial reductions in caloric intake.

GLP-1 receptor activation on pancreatic beta cells enhances glucose-dependent insulin secretion, improving glycemic control while minimizing hypoglycemia risk. GLP-1 also slows gastric emptying, reducing the rate at which nutrients enter the small intestine, which contributes to satiety and moderates postprandial glucose excursions.

GIP Receptor Activation

The GIP receptor component adds complementary effects that enhance weight loss and metabolic improvement: GIP acts on adipose tissue to influence lipid metabolism and insulin sensitivity. GIP may have central nervous system effects on energy homeostasis and body weight regulation that are additive with GLP-1.

Research suggests GIP can enhance GLP-1’s effects on insulin secretion through synergistic pancreatic effects.

Glucagon Receptor Activation

The glucagon receptor component represents the unique addition in RT GLP-3 compared to dual agonists, providing effects specifically designed to enhance energy expenditure and fat oxidation: glucagon powerfully increases energy expenditure through thermogenic effects, boosting metabolic rate and caloric burning.

Glucagon promotes hepatic fatty acid oxidation (fat burning in the liver) and reduces intrahepatic lipid accumulation, which is particularly beneficial for MASH/NAFLD. It also enhances peripheral fat oxidation in skeletal muscle and other tissues, and may improve lipid metabolism and cardiovascular risk profiles through multiple mechanisms.

Balanced Triple Receptor Signaling

The critical innovation in RT GLP-3 is the careful balancing of these three receptor activities – the glucagon receptor activation could theoretically raise blood glucose (glucagon’s classical effect), but this is counteracted by the concurrent GLP-1 receptor activation which lowers glucose through multiple mechanisms.

At the molecular level, all three target receptors are Gs-coupled GPCRs that signal through cyclic AMP (cAMP) and protein kinase A (PKA), creating coordinated intracellular signaling that comprehensively shifts metabolism toward a catabolic state favoring fat oxidation.

RT GLP-3 is currently in late-stage clinical development with ongoing safety evaluation through comprehensive Phase 3 trials, but existing Phase 1 and Phase 2 data provide substantial information about its safety profile.

The compound has demonstrated generally good tolerability in clinical trials to date, with a safety profile largely consistent with other incretin-based therapies (GLP-1 and GLP-1/GIP agonists) that have become standard treatments for obesity and type 2 diabetes.

Common Adverse Events

The most common adverse events in Phase 2 trials were gastrointestinal in nature, reflecting the class effects of GLP-1 receptor activation on gastric motility and central appetite pathways. These included nausea (reported by approximately 30-40% of participants on higher doses), diarrhea, vomiting, constipation, and abdominal discomfort.

Importantly, these GI effects were typically mild to moderate in severity, most pronounced during dose titration periods, transient with tendency to resolve over weeks even with continued treatment, and manageable with slower dose escalation protocols and supportive care. Trial discontinuation rates due to adverse events were modest (approximately 10-15% in higher dose groups).

Glycemic Safety

Of particular importance given the glucagon receptor agonism component of RT GLP-3 , there were no clinically significant increases in blood glucose or concerning hyperglycemic events despite glucagon’s classical glucose-raising effects – confirming that the GLP-1 component successfully counteracts glucagon’s impact on glucose homeostasis.

Hypoglycemia was uncommon and primarily limited to participants with type 2 diabetes who were taking concomitant diabetes medications known to cause hypoglycemia (sulfonylureas, insulin), rather than being caused by RT GLP-3 itself.

Cardiovascular and Other Safety Considerations

Cardiovascular safety monitoring in Phase 2 trials showed heart rate increases of approximately 2-4 beats per minute on average, similar to what has been observed with other GLP-1 agonists. No unexpected safety signals regarding pancreatitis, thyroid disorders, or other organ systems emerged.

RT GLP-3 is not approved for clinical use and is available only through clinical trials. Current evidence suggests its safety profile is manageable and consistent with the incretin class, with no major safety barriers identified to date.